Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The 6th Society of Hematologic Oncology (SOHO) Italy Annual Conference was held on February 25-26, 2025, in Rome, Italy, and virtually. This meeting brought together experts to discuss the latest in hematologic cancers.

SOHO Italy 2025

25–26 February 2025 | Rome, Italy

SOHO Italy 2025

25–26 February 2025 | Rome, Italy
The 6th Society of Hematologic Oncology (SOHO) Italy Annual Conference was held on February 25-26, 2025, in Rome, Italy, and virtually. This meeting brought together experts to discuss the latest in hematologic cancers.
The current management of extramedullary disease and plasma cell leukemia 2:36
The current management of extramedullary disease and plasma cell leukemia
Daniele Derudas • 3 Mar 2025
Strategies being explored to enhance the efficacy of CAR T-cells in hematological malignancies 5:04
Strategies being explored to enhance the efficacy of CAR T-cells in hematological malignancies
Massimiliano Mazza • 26 Feb 2025
The diagnosis of extramedullary disease and plasma cell leukemia 1:58
The diagnosis of extramedullary disease and plasma cell leukemia
Daniele Derudas • 3 Mar 2025
Optimizing reporting of infection rates in clinical trials of bispecific antibodies in myeloma 3:04
Optimizing reporting of infection rates in clinical trials of bispecific antibodies in myeloma
Joshua Richter • 4 Mar 2025
Novel strategies being explored to improve outcomes for patients with EMD or PCL 1:45
Novel strategies being explored to improve outcomes for patients with EMD or PCL
Daniele Derudas • 3 Mar 2025
LINKER-MM1 trial update and the potential approval of linvoseltamab for R/R myeloma 1:33
LINKER-MM1 trial update and the potential approval of linvoseltamab for R/R myeloma
Hans Lee • 26 Feb 2025
Looking to the future of CNS lymphoma management 1:36
Looking to the future of CNS lymphoma management
Andrés Ferreri • 28 Feb 2025
Novel agents for the treatment of CLL in Italy 2:06
Novel agents for the treatment of CLL in Italy
Antonio Cuneo • 27 Feb 2025
Toxicities associated with BCMA, GPRC5D & FcRH5-targeting bispecifics and advice on their management 2:46
Toxicities associated with BCMA, GPRC5D & FcRH5-targeting bispecifics and advice on their management
Joshua Richter • 4 Mar 2025
Challenges in the treatment of multiple myeloma in Brazil 2:18
Challenges in the treatment of multiple myeloma in Brazil
Angelo Maiolino • 26 Feb 2025
The standard of care for newly diagnosed AL amyloidosis and promising agents in the R/R space 1:46
The standard of care for newly diagnosed AL amyloidosis and promising agents in the R/R space
Hans Lee • 26 Feb 2025
Managing early relapses in multiple myeloma: bispecifics, ADCs & CAR-T 2:58
Managing early relapses in multiple myeloma: bispecifics, ADCs & CAR-T
Joshua Richter • 4 Mar 2025
What lies ahead for bispecifics in multiple myeloma? 2:02
What lies ahead for bispecifics in multiple myeloma?
Joshua Richter • 4 Mar 2025
The current standard approach to myeloma treatment in Brazil 2:36
The current standard approach to myeloma treatment in Brazil
Angelo Maiolino • 26 Feb 2025
The current role of brentuximab vedotin in Hodgkin lymphoma 1:34
The current role of brentuximab vedotin in Hodgkin lymphoma
Amanda Cashen • 25 Feb 2025
The evolving role of checkpoint inhibitors in the treatment of Hodgkin lymphoma 1:47
The evolving role of checkpoint inhibitors in the treatment of Hodgkin lymphoma
Amanda Cashen • 25 Feb 2025

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals